TY  - GEN
AU  - Moore,Kathleen N
AU  - Martin,Lainie P
AU  - O'Malley,David M
AU  - Matulonis,Ursula A
AU  - Konner,Jason A
AU  - Perez,Raymond P
AU  - Bauer,Todd M
AU  - Ruiz-Soto,Rodrigo
AU  - Birrer,Michael J
TI  - Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
SN  - 1527-7755
PY  - 2017///0808
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - adverse effects
KW  - Antineoplastic Agents
KW  - Diarrhea
KW  - chemically induced
KW  - Disease-Free Survival
KW  - Drug Resistance, Neoplasm
KW  - Fallopian Tube Neoplasms
KW  - chemistry
KW  - Fatigue
KW  - Female
KW  - Folate Receptor 1
KW  - analysis
KW  - Humans
KW  - Hypotension
KW  - Immunoconjugates
KW  - Maytansine
KW  - Middle Aged
KW  - Nausea
KW  - Ovarian Neoplasms
KW  - Peritoneal Neoplasms
KW  - Platinum Compounds
KW  - therapeutic use
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Retreatment
KW  - Vision Disorders
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1200/JCO.2016.69.9538
ER  -